Yiming Li

US Patent:

20200407423, Dec 31, 2020

Filed:

Jun 15, 2020

Appl. No.:

16/901812

Inventors:

- Gaithersburg MD, US
Mariko FONSECA - Gaithersburg MD, US
Christopher THOMPSON - Gaithersburg MD, US
Alan HUNTER - Gaithersburg MD, US
Xiangyang WANG - Gaithersburg MD, US
Liu TIE - Gaithersburg MD, US
Yiming LI - Gaithersburg MD, US

International Classification:

C07K 14/765
A61K 47/64
C07K 1/18
C07K 1/22
C07K 14/78

Abstract:

The present invention relates to a method of purifying albumin-fusion proteins to reduce the level of oxidation of susceptible amino acid residues. The method comprises an affinity matrix chromatography step and an anion exchange chromatography step. The purified albumin-fusion proteins have low levels of oxidation and retain their enhanced half-life in vivo and its bioactivity. In some embodiments, the albumin-fusion protein comprises a scaffold, such as human Tenascin C scaffold. Compositions comprising the albumin-fusion protein are further disclosed.

US Patent:

20180105575, Apr 19, 2018

Filed:

Mar 11, 2016

Appl. No.:

15/557358

Inventors:

- Gaithersburg MD, US
Mariko FONSECA - Gaithersburg MD, US
Christopher THOMPSON - Gaithersburg MD, US
Alan HUNTER - Gaithersburg MD, US
Xiangyang WANG - Gaithersburg MD, US
Liu TIE - Gaithersburg MD, US
Yiming LI - Gaithersburg MD, US

International Classification:

C07K 14/765
C07K 1/18
C07K 1/22
C07K 14/78

Abstract:

The present invention relates to a method of purifying albumin-fusion proteins to reduce the level of oxidation of susceptible amino acid residues. The method comprises an affinity matrix chromatography step and an anion exchange chromatography step. The purified albumin-fusion proteins have low levels of oxidation and retain their enhanced half-life in vivo and its bioactivity. In some embodiments, the albumin-fusion protein comprises a scaffold, such as human Tenascin C scaffold. Compositions comprising the albumin-fusion protein are further disclosed.